Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
Associated Therapies
-

Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates

Phase 3
Conditions
Interventions
First Posted Date
2008-02-20
Last Posted Date
2008-02-20
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
64
Registration Number
NCT00618852
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Nephropathy In Type 2 Diabetes and Cardio-renal Events

First Posted Date
2007-09-27
Last Posted Date
2020-08-03
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
850
Registration Number
NCT00535925
Locations
🇮🇹

Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy

Physiopathology of Sodium Retention in Acromegaly

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2007-09-19
Last Posted Date
2011-12-07
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
12
Registration Number
NCT00531908
Locations
🇫🇷

Hopital Bicetre, Paris, France

Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients

Phase 3
Completed
Conditions
First Posted Date
2007-08-08
Last Posted Date
2007-08-08
Lead Sponsor
Baqiyatallah Medical Sciences University
Registration Number
NCT00512811
Locations
🇮🇷

RCCI, Tehran, Iran, Islamic Republic of

Loop Diuretics in Chronic Kidney Disease

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-05-25
Last Posted Date
2009-02-04
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
40
Registration Number
NCT00478543
Locations
🇮🇹

Nephrology Department, Second University of Naples, Naples, Italy

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

First Posted Date
2006-12-12
Last Posted Date
2009-07-15
Lead Sponsor
Ferrer Internacional S.A.
Target Recruit Count
142
Registration Number
NCT00409942
Locations
🇪🇸

Central Hospital, Oviedo, Asturias, Spain

🇪🇸

Centelles - Primar Care Centre, Centellas, Barcelona, Spain

🇪🇸

San Jorge Hospital, Huesca, Spain

and more 20 locations

Bumetanide Versus Furosemide in Heart Failure

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2006-09-07
Last Posted Date
2014-03-27
Lead Sponsor
Lawson Health Research Institute
Registration Number
NCT00372762
Locations
🇨🇦

University Hospital, London Health Sciences Centre, London, Ontario, Canada

Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

Phase 4
Completed
Conditions
Interventions
First Posted Date
2006-07-24
Last Posted Date
2016-08-18
Lead Sponsor
Hyogo Medical University
Target Recruit Count
320
Registration Number
NCT00355667
Locations
🇯🇵

The Hospital of Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Phase 4
Completed
Conditions
First Posted Date
2006-03-24
Last Posted Date
2016-09-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
388
Registration Number
NCT00306696
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Forced Diuresis Versus Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients

Phase 3
Terminated
Conditions
First Posted Date
2006-03-02
Last Posted Date
2007-04-19
Lead Sponsor
Medical Centre Leeuwarden
Target Recruit Count
72
Registration Number
NCT00298454
Locations
🇳🇱

Dept of intensive care, Medical Centre Leeuwarden, Leeuwarden, Fr, Netherlands

© Copyright 2024. All Rights Reserved by MedPath